TY - JOUR
T1 - Three new cases of ataxia-telangiectasia-like disorder
T2 - No impairment of the ATM pathway, but S-phase checkpoint defect
AU - Fiévet, Alice
AU - Bellanger, Dorine
AU - Valence, Stéphanie
AU - Mobuchon, Lenha
AU - Afenjar, Alexandra
AU - Giuliano, Fabienne
AU - Dubois d'Enghien, Catherine
AU - Parfait, Béatrice
AU - Pedespan, Jean Michel
AU - Auger, Nathalie
AU - Rieunier, Guillaume
AU - Collet, Agnès
AU - Burglen, Lydie
AU - Stoppa-Lyonnet, Dominique
AU - Stern, Marc Henri
N1 - Publisher Copyright:
© 2019 Wiley Periodicals, Inc.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Ataxia-telangiectasia-like disorder (ATLD) is a rare genomic instability syndrome caused by biallelic variants of MRE11 (meiotic recombination 11) characterized by progressive cerebellar ataxia and typical karyotype abnormalities. These symptoms are common to those of ataxia-telangiectasia, which is consistent with the key role of MRE11 in ataxia-telangiectasia mutated (ATM) activation after DNA double-strand breaks. Three unrelated French patients were referred with ataxia. Only one had typical karyotype abnormalities. Unreported biallelic MRE11 variants were found in these three cases. Interestingly, one variant (c.424G>A) was present in two cases and haplotype analysis strongly suggested a French founder variant. Variants c.544G>A and c.314+4_314+7del lead to splice defects. The level of MRE11 in lymphoblastoid cell lines was consistently and dramatically reduced. Functional consequences were evaluated on activation of the ATM pathway via phosphorylation of ATM targets (KAP1 and CHK2), but no consistent defect was observed. However, an S-phase checkpoint activation defect after camptothecin was observed in these patients with ATLD. In conclusion, we report the first three French ATLD patients and a French founder variant, and propose an S-phase checkpoint activation study to evaluate the pathogenicity of MRE11 variants.
AB - Ataxia-telangiectasia-like disorder (ATLD) is a rare genomic instability syndrome caused by biallelic variants of MRE11 (meiotic recombination 11) characterized by progressive cerebellar ataxia and typical karyotype abnormalities. These symptoms are common to those of ataxia-telangiectasia, which is consistent with the key role of MRE11 in ataxia-telangiectasia mutated (ATM) activation after DNA double-strand breaks. Three unrelated French patients were referred with ataxia. Only one had typical karyotype abnormalities. Unreported biallelic MRE11 variants were found in these three cases. Interestingly, one variant (c.424G>A) was present in two cases and haplotype analysis strongly suggested a French founder variant. Variants c.544G>A and c.314+4_314+7del lead to splice defects. The level of MRE11 in lymphoblastoid cell lines was consistently and dramatically reduced. Functional consequences were evaluated on activation of the ATM pathway via phosphorylation of ATM targets (KAP1 and CHK2), but no consistent defect was observed. However, an S-phase checkpoint activation defect after camptothecin was observed in these patients with ATLD. In conclusion, we report the first three French ATLD patients and a French founder variant, and propose an S-phase checkpoint activation study to evaluate the pathogenicity of MRE11 variants.
KW - MRN
KW - ataxia
KW - ataxia-telangiectasia mutated (ATM)
KW - ataxia-telangiectasia-like disorder (ATLD)
KW - checkpoint
KW - meiotic recombination 11 (MRE11)
UR - http://www.scopus.com/inward/record.url?scp=85072716455&partnerID=8YFLogxK
U2 - 10.1002/humu.23773
DO - 10.1002/humu.23773
M3 - Article
C2 - 31033087
AN - SCOPUS:85072716455
SN - 1059-7794
VL - 40
SP - 1690
EP - 1699
JO - Human Mutation
JF - Human Mutation
IS - 10
ER -